Nkarta, Inc. (NASDAQ:NKTX – Get Rating) – Investment analysts at Oppenheimer reduced their FY2024 earnings per share (EPS) estimates for shares of Nkarta in a report released on Thursday, December 22nd. Oppenheimer analyst M. Biegler now forecasts that the company will post earnings of ($3.17) per share for the year, down from their prior forecast of ($3.07). Oppenheimer has a "Market Perform" rating on the stock. The consensus estimate for Nkarta's current full-year earnings is ($2.63) per share. Oppenheimer also issued estimates for Nkarta's FY2025 earnings at ($2.82) EPS and FY2026 earnings at ($2.75) EPS.

Several other research analysts have also commented on the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Nkarta in a research report on Wednesday, September 21st. Canaccord Genuity Group initiated coverage on Nkarta in a research report on Monday, October 10th. They set a "buy" rating and a $25.00 target price on the stock. Mizuho reduced their target price on Nkarta from $81.00 to $26.00 and set a "buy" rating on the stock in a research report on Wednesday, November 16th. Finally, Canaccord Genuity Group initiated coverage on Nkarta in a research report on Monday, October 10th. They set a "buy" rating and a $25.00 target price on the stock. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $29.90.

Nkarta Trading Up 0.7 %

Insider Buying and Selling at Nkarta

In other Nkarta news, CEO Paul J. Hastings sold 23,376 shares of the business's stock in a transaction dated Wednesday, September 28th. The stock was sold at an average price of $13.03, for a total transaction of $304,589.28. Following the sale, the chief executive officer now owns 250,959 shares in the company, valued at approximately $3,269,995.77. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 5.60% of the company's stock.

Institutional Trading of Nkarta

Hedge funds have recently modified their holdings of the stock. Parkwood LLC purchased a new stake in shares of Nkarta in the second quarter worth about $31,000. Quantbot Technologies LP boosted its position in Nkarta by 39.1% during the first quarter. Quantbot Technologies LP now owns 3,200 shares of the company's stock worth $36,000 after purchasing an additional 900 shares in the last quarter. Denali Advisors LLC purchased a new position in Nkarta during the second quarter worth approximately $38,000. Point72 Hong Kong Ltd purchased a new position in Nkarta during the third quarter worth approximately $46,000. Finally, Federated Hermes Inc. boosted its position in Nkarta by 735.3% during the first quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock worth $54,000 after purchasing an additional 4,147 shares in the last quarter. Hedge funds and other institutional investors own 87.22% of the company's stock.

About Nkarta

(Get Rating)

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

See Also

• Get a free copy of the StockNews.com research report on Nkarta (NKTX)
• MarketBeat: Week in Review 12/19 – 12/23
• These Steelmakers Deserve A Place On Your 2023 Watch List
• Inflation Cools, Where Does The S&P 500 Go Now
• Cintas Beats Inflation With Operating Leverage
• Your Decision to Buy Palantir May Simply Be a Matter of Time

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.